60 Degrees Pharmaceuticals has commenced a nine-month promotional pilot to bring greater awareness of Arakoda and its benefits to patients and healthcare providers who prescribe it. Arakoda is an antimalarial indicated for the prevention of malaria in patients aged 18 years and older. The pilot program includes inside, or virtual, sales representatives who will conduct outreach to prospective and current Arakoda customers to promote the co-pay program and increase sales. Part of the pilot entails development of a co-pay assistance program to assist with out-of-pocket costs for people traveling to malaria-endemic regions. Arakoda is the only FDA-approved prophylactic therapy approved by the FDA that provides protection against all stages of malaria.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP:
- 60 Degrees Pharmaceuticals to sell 2.9M shares at $1.38 in private placement
- 60 Degrees Pharmaceuticals regains compliance with Nasdaq listing requirements
- 60 Degrees granted University of Kentucky right to reference NDA for ARAKODA
- 60 Degrees Pharmaceuticals Inc trading halted, news pending
- 60 Degrees Pharmaceuticals announces 1-for-12 reverse stock split